Effects of postmenopausal hormone replacement therapy on body fat composition
Aim. To evaluate the effects of different types, regimens and administration routes of hormone replacement therapy (HRT) on body fat composition indices in postmenopausal women at increased risk of anthropometry-related cardiovascular disease (CVD). Methods. Fifty-nine postmenopausal women (aged 41-...
Gespeichert in:
| Veröffentlicht in: | Gynecological endocrinology 2007-02, Vol.23 (2), p.99-104 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 104 |
|---|---|
| container_issue | 2 |
| container_start_page | 99 |
| container_title | Gynecological endocrinology |
| container_volume | 23 |
| creator | Yüksel, Hasan Odaba i, Ali Riza Demircan, Selda Köseo lu, Kutsi Kizilkaya, Kadir Onur, Ergün |
| description | Aim. To evaluate the effects of different types, regimens and administration routes of hormone replacement therapy (HRT) on body fat composition indices in postmenopausal women at increased risk of anthropometry-related cardiovascular disease (CVD).
Methods. Fifty-nine postmenopausal women (aged 41-57 years, mean ± standard deviation: 49.9 ± 3.8 years) with body mass index (BMI) ≥25 kg m2 participated in this 6-month, prospective, randomized single-blind study. Subjects were assigned into three groups and received transdermal estradiol (E2) norethisterone acetate (NETA) (50 μg E2 daily for 14 days followed by 50 μg E2 0.25 μg NETA daily for 14 days; transdermal group, n = 19), transdermal continuous E2 oral medroxyprogesterone acetate (MPA) (50 μg E2 5 mg MPA daily; transdermal oral group, n = 19) or oral continuous E2 NETA (1 mg E2 0.5 mg NETA daily; oral group, n = 21). Anthropometric indices (body weight, height, and hip and waist circumferences) were measured, and BMI and waist-to-hip ratio (WHR) were calculated, before and after treatment. Also, the thickness of subcutaneous abdominal fat was measured by ultrasound. Depending on waist circumference (WC), the subjects were divided into two risk groups: increased-risk group with WC 0.05) between HRT groups. In each group, all types of HRT significantly decreased WC and subcutaneous fat (transdermal group: p < 0.001 and p < 0.05; transdermal oral group: p < 0.001 and p < 0.01; oral group: p < 0.001 and p < 0.001, respectively), while body weight, BMI and WHR changed only insignificantly (p > 0.05). In the increased-risk group, body weight increased significantly (p < 0.05) while WC and subcutaneous fat decreased significantly (p < 0.001 and p < 0.001). As for the high-risk group, there was a significant decrease in WC and subcutaneous fat (p < 0.001, p < 0.001) while the remaining parameters did not change significantly. However, BMI showed a tendency to increase in the increased-risk group, while there was a decrease in all measurements in the high-risk gr |
| doi_str_mv | 10.1080/09513590601152177 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_17454160</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1275840171</sourcerecordid><originalsourceid>FETCH-LOGICAL-c431t-5d1144148efef3719fb5332088c91a059afeaac31ece15563b87c042ce703fd3</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotlZ_gBcJ3lczm2Szi16k1A-oeOl9SbMTumV3syYp0n_vlhZURE9zmOd5h3kJuQR2Ayxnt6yQwGXBMgYgU1DqiIxBKJ4wlWXHZLzbJztgRM5CWDMGXKj0lIxACSkgY2PyOrMWTQzUWdq7EFvsXK83QTd05XzrOqQe-0YbHDaRxhV63W-p6-jSVVtqdaTGtYNZx9p15-TE6ibgxWFOyOJxtpg-J_O3p5fpwzwxgkNMZAUgBIgcLVquoLBLyXnK8twUoJkstEWtDQc0CFJmfJkrw0RqUDFuKz4h1_vY3rv3DYZYrt3Gd8PFEgolUg5ZMUCwh4x3IXi0Ze_rVvttCazc1Vf-qm9wrg7Bm2WL1Zdx6GsA7vdA3dmhHv3hfFOVUW8b563XnalDyf_Lv_uhr1A3cWW0x28f_Gl_Ao7_j_I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>197423169</pqid></control><display><type>article</type><title>Effects of postmenopausal hormone replacement therapy on body fat composition</title><source>MEDLINE</source><source>Taylor & Francis Journals Complete</source><creator>Yüksel, Hasan ; Odaba i, Ali Riza ; Demircan, Selda ; Köseo lu, Kutsi ; Kizilkaya, Kadir ; Onur, Ergün</creator><creatorcontrib>Yüksel, Hasan ; Odaba i, Ali Riza ; Demircan, Selda ; Köseo lu, Kutsi ; Kizilkaya, Kadir ; Onur, Ergün</creatorcontrib><description><![CDATA[Aim. To evaluate the effects of different types, regimens and administration routes of hormone replacement therapy (HRT) on body fat composition indices in postmenopausal women at increased risk of anthropometry-related cardiovascular disease (CVD).
Methods. Fifty-nine postmenopausal women (aged 41-57 years, mean ± standard deviation: 49.9 ± 3.8 years) with body mass index (BMI) ≥25 kg m2 participated in this 6-month, prospective, randomized single-blind study. Subjects were assigned into three groups and received transdermal estradiol (E2) norethisterone acetate (NETA) (50 μg E2 daily for 14 days followed by 50 μg E2 0.25 μg NETA daily for 14 days; transdermal group, n = 19), transdermal continuous E2 oral medroxyprogesterone acetate (MPA) (50 μg E2 5 mg MPA daily; transdermal oral group, n = 19) or oral continuous E2 NETA (1 mg E2 0.5 mg NETA daily; oral group, n = 21). Anthropometric indices (body weight, height, and hip and waist circumferences) were measured, and BMI and waist-to-hip ratio (WHR) were calculated, before and after treatment. Also, the thickness of subcutaneous abdominal fat was measured by ultrasound. Depending on waist circumference (WC), the subjects were divided into two risk groups: increased-risk group with WC <88 cm (n = 32) and high-risk group with WC ≥88 cm (n = 27). Also, the effects of HRT were evaluated separately in subjects with median subcutaneous fat of <33 mm (n = 29) and those with median subcutaneous fat of ≥33 mm (n = 30).
Results. Overall, all three types of HRT caused a significant decrease in both WC and subcutaneous fat (p < 0.001), and also in WHR (p < 0.05). There was no significant difference in baseline (p > 0.05) and final values (p > 0.05) between HRT groups. In each group, all types of HRT significantly decreased WC and subcutaneous fat (transdermal group: p < 0.001 and p < 0.05; transdermal oral group: p < 0.001 and p < 0.01; oral group: p < 0.001 and p < 0.001, respectively), while body weight, BMI and WHR changed only insignificantly (p > 0.05). In the increased-risk group, body weight increased significantly (p < 0.05) while WC and subcutaneous fat decreased significantly (p < 0.001 and p < 0.001). As for the high-risk group, there was a significant decrease in WC and subcutaneous fat (p < 0.001, p < 0.001) while the remaining parameters did not change significantly. However, BMI showed a tendency to increase in the increased-risk group, while there was a decrease in all measurements in the high-risk group. Regardless of the drugs used and baseline subcutaneous fat, WC and subcutaneous fat decreased significantly at the end of the treatment (subcutaneous fat <33 mm: p < 0.001 and p < 0.01; subcutaneous fat ≥33 mm: p < 0.001 and p < 0.001, respectively).
Conclusions. The three different types of HRT have comparable effects on central fat tissue in women at increased risk of anthropometry-related CVD. Indeed, the three combinations of HRT reduced fat tissue in the central part of the body. However, the overall effect of HRT was more marked in women with WC ≥88 cm and subcutaneous fat ≥33 cm. Whether HRT increases body weight depends on the body composition indices of individuals before treatment.]]></description><identifier>ISSN: 0951-3590</identifier><identifier>EISSN: 1473-0766</identifier><identifier>DOI: 10.1080/09513590601152177</identifier><identifier>PMID: 17454160</identifier><identifier>CODEN: GYENER</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Abdominal Fat - drug effects ; Administration, Cutaneous ; Administration, Oral ; Adult ; body composition ; Body fat ; Body Fat Distribution ; Body Weight ; Cardiovascular Diseases - epidemiology ; Drug Combinations ; estradiol ; Estradiol - pharmacology ; Estrogen Replacement Therapy - adverse effects ; Estrogen Replacement Therapy - methods ; Female ; Humans ; medroxyprogesterone acetate ; Medroxyprogesterone Acetate - pharmacology ; Menopause ; Middle Aged ; Norethindrone - pharmacology ; norethisterone acetate ; Risk Factors ; subcutaneous fat ; Waist-Hip Ratio</subject><ispartof>Gynecological endocrinology, 2007-02, Vol.23 (2), p.99-104</ispartof><rights>2007 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2007</rights><rights>Copyright Taylor & Francis Ltd. Feb 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c431t-5d1144148efef3719fb5332088c91a059afeaac31ece15563b87c042ce703fd3</citedby><cites>FETCH-LOGICAL-c431t-5d1144148efef3719fb5332088c91a059afeaac31ece15563b87c042ce703fd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/09513590601152177$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/09513590601152177$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,59620,60409,61194,61375</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17454160$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yüksel, Hasan</creatorcontrib><creatorcontrib>Odaba i, Ali Riza</creatorcontrib><creatorcontrib>Demircan, Selda</creatorcontrib><creatorcontrib>Köseo lu, Kutsi</creatorcontrib><creatorcontrib>Kizilkaya, Kadir</creatorcontrib><creatorcontrib>Onur, Ergün</creatorcontrib><title>Effects of postmenopausal hormone replacement therapy on body fat composition</title><title>Gynecological endocrinology</title><addtitle>Gynecol Endocrinol</addtitle><description><![CDATA[Aim. To evaluate the effects of different types, regimens and administration routes of hormone replacement therapy (HRT) on body fat composition indices in postmenopausal women at increased risk of anthropometry-related cardiovascular disease (CVD).
Methods. Fifty-nine postmenopausal women (aged 41-57 years, mean ± standard deviation: 49.9 ± 3.8 years) with body mass index (BMI) ≥25 kg m2 participated in this 6-month, prospective, randomized single-blind study. Subjects were assigned into three groups and received transdermal estradiol (E2) norethisterone acetate (NETA) (50 μg E2 daily for 14 days followed by 50 μg E2 0.25 μg NETA daily for 14 days; transdermal group, n = 19), transdermal continuous E2 oral medroxyprogesterone acetate (MPA) (50 μg E2 5 mg MPA daily; transdermal oral group, n = 19) or oral continuous E2 NETA (1 mg E2 0.5 mg NETA daily; oral group, n = 21). Anthropometric indices (body weight, height, and hip and waist circumferences) were measured, and BMI and waist-to-hip ratio (WHR) were calculated, before and after treatment. Also, the thickness of subcutaneous abdominal fat was measured by ultrasound. Depending on waist circumference (WC), the subjects were divided into two risk groups: increased-risk group with WC <88 cm (n = 32) and high-risk group with WC ≥88 cm (n = 27). Also, the effects of HRT were evaluated separately in subjects with median subcutaneous fat of <33 mm (n = 29) and those with median subcutaneous fat of ≥33 mm (n = 30).
Results. Overall, all three types of HRT caused a significant decrease in both WC and subcutaneous fat (p < 0.001), and also in WHR (p < 0.05). There was no significant difference in baseline (p > 0.05) and final values (p > 0.05) between HRT groups. In each group, all types of HRT significantly decreased WC and subcutaneous fat (transdermal group: p < 0.001 and p < 0.05; transdermal oral group: p < 0.001 and p < 0.01; oral group: p < 0.001 and p < 0.001, respectively), while body weight, BMI and WHR changed only insignificantly (p > 0.05). In the increased-risk group, body weight increased significantly (p < 0.05) while WC and subcutaneous fat decreased significantly (p < 0.001 and p < 0.001). As for the high-risk group, there was a significant decrease in WC and subcutaneous fat (p < 0.001, p < 0.001) while the remaining parameters did not change significantly. However, BMI showed a tendency to increase in the increased-risk group, while there was a decrease in all measurements in the high-risk group. Regardless of the drugs used and baseline subcutaneous fat, WC and subcutaneous fat decreased significantly at the end of the treatment (subcutaneous fat <33 mm: p < 0.001 and p < 0.01; subcutaneous fat ≥33 mm: p < 0.001 and p < 0.001, respectively).
Conclusions. The three different types of HRT have comparable effects on central fat tissue in women at increased risk of anthropometry-related CVD. Indeed, the three combinations of HRT reduced fat tissue in the central part of the body. However, the overall effect of HRT was more marked in women with WC ≥88 cm and subcutaneous fat ≥33 cm. Whether HRT increases body weight depends on the body composition indices of individuals before treatment.]]></description><subject>Abdominal Fat - drug effects</subject><subject>Administration, Cutaneous</subject><subject>Administration, Oral</subject><subject>Adult</subject><subject>body composition</subject><subject>Body fat</subject><subject>Body Fat Distribution</subject><subject>Body Weight</subject><subject>Cardiovascular Diseases - epidemiology</subject><subject>Drug Combinations</subject><subject>estradiol</subject><subject>Estradiol - pharmacology</subject><subject>Estrogen Replacement Therapy - adverse effects</subject><subject>Estrogen Replacement Therapy - methods</subject><subject>Female</subject><subject>Humans</subject><subject>medroxyprogesterone acetate</subject><subject>Medroxyprogesterone Acetate - pharmacology</subject><subject>Menopause</subject><subject>Middle Aged</subject><subject>Norethindrone - pharmacology</subject><subject>norethisterone acetate</subject><subject>Risk Factors</subject><subject>subcutaneous fat</subject><subject>Waist-Hip Ratio</subject><issn>0951-3590</issn><issn>1473-0766</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kE1LAzEQhoMotlZ_gBcJ3lczm2Szi16k1A-oeOl9SbMTumV3syYp0n_vlhZURE9zmOd5h3kJuQR2Ayxnt6yQwGXBMgYgU1DqiIxBKJ4wlWXHZLzbJztgRM5CWDMGXKj0lIxACSkgY2PyOrMWTQzUWdq7EFvsXK83QTd05XzrOqQe-0YbHDaRxhV63W-p6-jSVVtqdaTGtYNZx9p15-TE6ibgxWFOyOJxtpg-J_O3p5fpwzwxgkNMZAUgBIgcLVquoLBLyXnK8twUoJkstEWtDQc0CFJmfJkrw0RqUDFuKz4h1_vY3rv3DYZYrt3Gd8PFEgolUg5ZMUCwh4x3IXi0Ze_rVvttCazc1Vf-qm9wrg7Bm2WL1Zdx6GsA7vdA3dmhHv3hfFOVUW8b563XnalDyf_Lv_uhr1A3cWW0x28f_Gl_Ao7_j_I</recordid><startdate>20070201</startdate><enddate>20070201</enddate><creator>Yüksel, Hasan</creator><creator>Odaba i, Ali Riza</creator><creator>Demircan, Selda</creator><creator>Köseo lu, Kutsi</creator><creator>Kizilkaya, Kadir</creator><creator>Onur, Ergün</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><general>Taylor & Francis Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>S0X</scope></search><sort><creationdate>20070201</creationdate><title>Effects of postmenopausal hormone replacement therapy on body fat composition</title><author>Yüksel, Hasan ; Odaba i, Ali Riza ; Demircan, Selda ; Köseo lu, Kutsi ; Kizilkaya, Kadir ; Onur, Ergün</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c431t-5d1144148efef3719fb5332088c91a059afeaac31ece15563b87c042ce703fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Abdominal Fat - drug effects</topic><topic>Administration, Cutaneous</topic><topic>Administration, Oral</topic><topic>Adult</topic><topic>body composition</topic><topic>Body fat</topic><topic>Body Fat Distribution</topic><topic>Body Weight</topic><topic>Cardiovascular Diseases - epidemiology</topic><topic>Drug Combinations</topic><topic>estradiol</topic><topic>Estradiol - pharmacology</topic><topic>Estrogen Replacement Therapy - adverse effects</topic><topic>Estrogen Replacement Therapy - methods</topic><topic>Female</topic><topic>Humans</topic><topic>medroxyprogesterone acetate</topic><topic>Medroxyprogesterone Acetate - pharmacology</topic><topic>Menopause</topic><topic>Middle Aged</topic><topic>Norethindrone - pharmacology</topic><topic>norethisterone acetate</topic><topic>Risk Factors</topic><topic>subcutaneous fat</topic><topic>Waist-Hip Ratio</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yüksel, Hasan</creatorcontrib><creatorcontrib>Odaba i, Ali Riza</creatorcontrib><creatorcontrib>Demircan, Selda</creatorcontrib><creatorcontrib>Köseo lu, Kutsi</creatorcontrib><creatorcontrib>Kizilkaya, Kadir</creatorcontrib><creatorcontrib>Onur, Ergün</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>SIRS Editorial</collection><jtitle>Gynecological endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yüksel, Hasan</au><au>Odaba i, Ali Riza</au><au>Demircan, Selda</au><au>Köseo lu, Kutsi</au><au>Kizilkaya, Kadir</au><au>Onur, Ergün</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of postmenopausal hormone replacement therapy on body fat composition</atitle><jtitle>Gynecological endocrinology</jtitle><addtitle>Gynecol Endocrinol</addtitle><date>2007-02-01</date><risdate>2007</risdate><volume>23</volume><issue>2</issue><spage>99</spage><epage>104</epage><pages>99-104</pages><issn>0951-3590</issn><eissn>1473-0766</eissn><coden>GYENER</coden><abstract><![CDATA[Aim. To evaluate the effects of different types, regimens and administration routes of hormone replacement therapy (HRT) on body fat composition indices in postmenopausal women at increased risk of anthropometry-related cardiovascular disease (CVD).
Methods. Fifty-nine postmenopausal women (aged 41-57 years, mean ± standard deviation: 49.9 ± 3.8 years) with body mass index (BMI) ≥25 kg m2 participated in this 6-month, prospective, randomized single-blind study. Subjects were assigned into three groups and received transdermal estradiol (E2) norethisterone acetate (NETA) (50 μg E2 daily for 14 days followed by 50 μg E2 0.25 μg NETA daily for 14 days; transdermal group, n = 19), transdermal continuous E2 oral medroxyprogesterone acetate (MPA) (50 μg E2 5 mg MPA daily; transdermal oral group, n = 19) or oral continuous E2 NETA (1 mg E2 0.5 mg NETA daily; oral group, n = 21). Anthropometric indices (body weight, height, and hip and waist circumferences) were measured, and BMI and waist-to-hip ratio (WHR) were calculated, before and after treatment. Also, the thickness of subcutaneous abdominal fat was measured by ultrasound. Depending on waist circumference (WC), the subjects were divided into two risk groups: increased-risk group with WC <88 cm (n = 32) and high-risk group with WC ≥88 cm (n = 27). Also, the effects of HRT were evaluated separately in subjects with median subcutaneous fat of <33 mm (n = 29) and those with median subcutaneous fat of ≥33 mm (n = 30).
Results. Overall, all three types of HRT caused a significant decrease in both WC and subcutaneous fat (p < 0.001), and also in WHR (p < 0.05). There was no significant difference in baseline (p > 0.05) and final values (p > 0.05) between HRT groups. In each group, all types of HRT significantly decreased WC and subcutaneous fat (transdermal group: p < 0.001 and p < 0.05; transdermal oral group: p < 0.001 and p < 0.01; oral group: p < 0.001 and p < 0.001, respectively), while body weight, BMI and WHR changed only insignificantly (p > 0.05). In the increased-risk group, body weight increased significantly (p < 0.05) while WC and subcutaneous fat decreased significantly (p < 0.001 and p < 0.001). As for the high-risk group, there was a significant decrease in WC and subcutaneous fat (p < 0.001, p < 0.001) while the remaining parameters did not change significantly. However, BMI showed a tendency to increase in the increased-risk group, while there was a decrease in all measurements in the high-risk group. Regardless of the drugs used and baseline subcutaneous fat, WC and subcutaneous fat decreased significantly at the end of the treatment (subcutaneous fat <33 mm: p < 0.001 and p < 0.01; subcutaneous fat ≥33 mm: p < 0.001 and p < 0.001, respectively).
Conclusions. The three different types of HRT have comparable effects on central fat tissue in women at increased risk of anthropometry-related CVD. Indeed, the three combinations of HRT reduced fat tissue in the central part of the body. However, the overall effect of HRT was more marked in women with WC ≥88 cm and subcutaneous fat ≥33 cm. Whether HRT increases body weight depends on the body composition indices of individuals before treatment.]]></abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>17454160</pmid><doi>10.1080/09513590601152177</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0951-3590 |
| ispartof | Gynecological endocrinology, 2007-02, Vol.23 (2), p.99-104 |
| issn | 0951-3590 1473-0766 |
| language | eng |
| recordid | cdi_pubmed_primary_17454160 |
| source | MEDLINE; Taylor & Francis Journals Complete |
| subjects | Abdominal Fat - drug effects Administration, Cutaneous Administration, Oral Adult body composition Body fat Body Fat Distribution Body Weight Cardiovascular Diseases - epidemiology Drug Combinations estradiol Estradiol - pharmacology Estrogen Replacement Therapy - adverse effects Estrogen Replacement Therapy - methods Female Humans medroxyprogesterone acetate Medroxyprogesterone Acetate - pharmacology Menopause Middle Aged Norethindrone - pharmacology norethisterone acetate Risk Factors subcutaneous fat Waist-Hip Ratio |
| title | Effects of postmenopausal hormone replacement therapy on body fat composition |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T12%3A37%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20postmenopausal%20hormone%20replacement%20therapy%20on%20body%20fat%20composition&rft.jtitle=Gynecological%20endocrinology&rft.au=Y%C3%BCksel,%20Hasan&rft.date=2007-02-01&rft.volume=23&rft.issue=2&rft.spage=99&rft.epage=104&rft.pages=99-104&rft.issn=0951-3590&rft.eissn=1473-0766&rft.coden=GYENER&rft_id=info:doi/10.1080/09513590601152177&rft_dat=%3Cproquest_pubme%3E1275840171%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=197423169&rft_id=info:pmid/17454160&rfr_iscdi=true |